CLYM earnings analysis
What we found in CLYM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Climb Bio reported significant improvements in net loss and R&D expenses for Q1 2026. While total revenue figures were not provided, the net loss was reduced to $13.7 million compared to $20.8 million in Q1 2025. The company achieved a decrease in R&D expenses from $17.3 million to $9.4 million, indicating improved cost management amidst ongoing clinical trials and development efforts for its product candidates.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Net loss fell to $13.7 million from $20.8 million year-over-year.
- Decreased R&D Expenses
- R&D expenses decreased significantly from $17.3 million to $9.4 million, indicating better cost management.
- Strengthened Cash Position
- As of March 31, 2026, cash and cash equivalents totaled $146.3 million.
- Progress on Clinical Trials
- Advanced clinical trials for budoprutug with initial data expected in Q4 2026.
- Private Placement Financing
- Raised $110 million through a private placement in April 2026.
- Regulatory Designation Achievements
- Received FastTrack and orphan-drug designations for budoprutug.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Operating Losses
- Expect continued significant losses as cash reserves are projected to fund operations into 2028.
- Dependence on Key Personnel
- Disruption in management due to turnover could impede current development projects.
- Regulatory Approval Risks
- Remaining uncertain about the outcome of trials for budoprutug and CLYM116 could delay commercialization.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
What they said about what is next.
Management anticipates continued investment in R&D while managing cash burn.
The filing reads better than the one before it.
What came before.
- 10-K · March 5, 2026
- Climb Bio (CLYM) is a clinical-stage biotech focused on CD19 (budoprutug) and APRIL (CLYM116) programs for immune-mediated diseases; the 10-K highlights clinical progression (PrisMN Phase 2 FPI Nov 2025, multiple Phase…
- 10-Q · August 12, 2025
- Climb Bio reported a much smaller GAAP net loss in Q2 2025 of $(8,666)k (EPS $(0.13)), a large improvement from Q2 2024 net loss of $(54,889)k (EPS $(1.81)). Operating expenses fell to $10,677k this quarter versus…
- 10-Q · May 14, 2025
- Climb Bio reported a net loss of $20.8M (GAAP) or $(0.31) per share for the quarter ended March 31, 2025, driven by a sharp R&D spend ramp. The company holds $29.0M in cash and $168.8M in marketable securities (combined…
- 10-K · March 25, 2025
- Climb Bio positions itself as a clinical-stage, B‑cell focused biotech building a two‑asset pipeline centered on budoprutug (anti‑CD19) and CLYM116 (anti‑APRIL) acquired/licensed via the Tenet acquisition (June 2024)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLYM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever